Skip to main content
TipRanks
Go Ultimate75% OFF

Sangamo Therapeutics (0R1D) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Sangamo Therapeutics has a market cap or net worth of $48.47M. The enterprise value is $87.94M.

Market Cap
$48.47M
Enterprise Value
$87.94M

Share Statistics

Sangamo Therapeutics has 414,288,850 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
414,288,850
Owned by Insiders
0.94%
Owned by Institutions
1.73%

Financial Efficiency

Sangamo Therapeutics’s return on equity (ROE) is 8.62 and return on invested capital (ROIC) is -566.39%.

Return on Equity (ROE)
8.62
Return on Assets (ROA)
-2.06
Return on Invested Capital (ROIC)
-566.39%
Return on Capital Employed (ROCE)
-6.25
Revenue Per Employee
278.54K
Profits Per Employee
-865.72K
Employee Count
142
Asset Turnover
0.66
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Sangamo Therapeutics is -0.20. Sangamo Therapeutics’s PEG ratio is 0.01.

PE Ratio
-0.20
PS Ratio
0.89
PB Ratio
-1.52
Price to FCF
-0.34
Price to Operating Cash Flow
-0.32
PEG Ratio
0.01

Income Statement

In the last 12 months, Sangamo Therapeutics had revenue of 39.55M and earned -122.93M in profits. Earnings per share was -0.44.

Revenue
39.55M
Gross Profit
31.95M
Operating Income
-108.00M
Pretax Income
-123.50M
Net Income
-122.93M
EBITDA
-115.90M
Earnings Per Share (EPS)
-0.44

Cash Flow

In the last 12 months, operating cash flow was -90.34M and capital expenditures -115,000, giving a free cash flow of -90.46M billion.

Operating Cash Flow
-90.34M
Free Cash Flow
-90.46M
Free Cash Flow per Share
-0.23

Dividends & Yields

Sangamo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-122.32%
Earnings Yield
-177.33%

Stock Price Statistics

Beta
0.45
52-Week Price Change
-75.79%
50-Day Moving Average
0.13
200-Day Moving Average
0.19
Relative Strength Index (RSI)
45.32
Average Volume (3m)
55.10K

Important Dates

Sangamo Therapeutics upcoming earnings date is Feb 24, 2027, TBA (Not Confirmed).

Last Earnings Date
Oct 29, 2026
Next Earnings Date
Feb 24, 2027
Ex-Dividend Date
―

Financial Position

Sangamo Therapeutics as a current ratio of 0.84, with Debt / Equity ratio of -187.80%

Current Ratio
0.84
Quick Ratio
0.84
Debt to Market Cap
0.00
Net Debt to EBITDA
-0.05
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Sangamo Therapeutics has paid -568.00K in taxes.

Income Tax
-568.00K
Effective Tax Rate
0.00

Enterprise Valuation

Sangamo Therapeutics EV to EBITDA ratio is -0.56, with an EV/FCF ratio of -0.73.

EV to Sales
1.90
EV to EBITDA
-0.56
EV to Free Cash Flow
-0.73
EV to Operating Cash Flow
-0.73

Balance Sheet

Sangamo Therapeutics has $27.59M in cash and marketable securities with $19.33M in debt, giving a net cash position of $8.25M billion.

Cash & Marketable Securities
$27.59M
Total Debt
$19.33M
Net Cash
$8.25M
Net Cash Per Share
$0.02
Tangible Book Value Per Share
-$0.05

Margins

Gross margin is 100.00%, with operating margin of -319.25%, and net profit margin of -356.89%.

Gross Margin
100.00%
Operating Margin
-319.25%
Pretax Margin
-358.88%
Net Profit Margin
-356.89%
EBITDA Margin
-339.91%
EBIT Margin
-358.88%

Analyst Forecast

The average price target for Sangamo Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
-45.80%
EPS Growth Forecast
-0.16%

Scores

Smart Score
3
AI Score
―